In the first half of this year, the domestic immune anticancer drug market surpassed 200 billion won. In particular, Opdivo's performance, which showed his endurance, was remarkable. Opdivo sales increased 41% from the previous year, surpassing 50 billion won in half-year sales.

According to IQVIA, a pharmaceutical market research firm, the size of the domestic immuno-cancer drug market in the first half of this year was 215.8 billion won, up 17.2% from 184.1 billion won a year earlier. The drug leading this market is MSD's Keytruda, which has the most indications. Keytruda posted 94.4 billion won in sales in the first half of this year, up 1.2% from the previous year. Sales seemed to be decreasing from